Application of Precision Partial Intersphincteric Resection (PPISR)

Application of Precision Partial Intersphincteric Resection (PPISR) in Patients With Ultra-low Rectal Cancer

The goal of this study is to establish a standardized operating procedure for Precision Partial Intersphincteric Resection (PPISR), and to evaluate its surgical safety, functional benefits, and oncological efficacy.

Study Overview

Study Type

Interventional

Enrollment (Estimated)

100

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

    • Zhejiang
      • Wenzhou, Zhejiang, China, 325000
        • Recruiting
        • First Affiliated Hospital of Wenzhou Medical University
        • Contact:
          • chunwu zhang
          • Phone Number: 86+0577-55578055

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 75 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Patients aged 18-75 years old
  • Pathology suggestive of moderately to highly differentiated rectal adenocarcinoma
  • Tumor lower margin ≤ 5 cm from the anal verge
  • Pre-operative tumor (T) staging of T1-T3 and T1-T2 below the level of the anal raphe muscle
  • No distant metastasis such as lung, liver and other organs

Exclusion Criteria:

  • Preoperative patients with severe underlying diseases (such as severe liver and kidney function, cardiopulmonary function, coagulation dysfunction, etc.)
  • Patients with malignant tumors in other parts of the body
  • Patients who underwent emergency surgery due to acute perforation, obstruction, etc.
  • Patients with tumor infiltration of peripheral organs during the operation, which required combined resection or palliative resection
  • Patients who had a mid-opening laparoscopic operation for various reasons -during the operation
  • Patients with poor anal function before operation, which is not suitable for anus preservation surgery.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: PPISR

The experimental group underwent the PPISR procedure.

The experimental group underwent the PPISR procedure. The surgical process was as follows:

  1. The abdominal team performed the TME procedure, completely resecting the mesorectum at the level of the mesorectum termination line within the levator hiatus.
  2. The transanal team completed routine preoperative preparation and disinfection, and located the distal and lateral resection margins of the tumor (with a margin distance ≥5 mm from the tumor boundary), thereby preserving part of the internal anal sphincter and normal intestinal wall tissue.
  3. A "U"-shaped dissection was performed cranially along the marking line within the intersphincteric space, meeting the abdominal team at the level of the levator hiatus, as shown in Figure 1.
  4. The specimen was removed either transanally or transabdominally.
  5. The proximal intestinal segment was trimmed, intestinal anastomosis was performed manually, and the procedure was concluded.
Active Comparator: Traditional ISR

The control group underwent the traditional ISR procedure

The control group underwent the traditional ISR procedure. The surgical process was as follows:

  1. The abdominal team entered the abdominal cavity and mobilized the sigmoid colon and rectum according to the principle of total mesorectal excision (TME). The vessels were ligated at a high position, and the rectum was dissected downward along the presacral space to the level of the levator ani muscle (pelvic floor), fully exposing the distal rectum and the levator ani muscle.
  2. The transanal team made a full-thickness circumferential incision in the rectal mucosa slightly above the dentate line (approximately ≥1 cm), entering the intersphincteric groove. A sharp circumferential dissection was performed along this groove to "pull" the rectum (along with its internal sphincter) out from within the external anal sphincter. During this dissection, care was taken to avoid damaging the external sphincter complex and its innervation.
  3. When the perineal dissection plane reached the level of

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Postoperative anal function as assessed by Wexner Score
Time Frame: At 3 and 6 months postoperatively

Scale Title: Wexner Fecal Incontinence Score. The minimum values:0. The maximum values:20. Higher scores mean a worse outcome.

At 3 and 6 months postoperatively
Postoperative quality of life as assessed by EORTC QLQ-C30
Time Frame: At 1 year postoperatively

Scale Title: European Organization for Research and Treatment of cancer Quality of Life Questionnaire. The minimum values:0. The maximum values:100. Higher scores mean a worse outcome.

At 1 year postoperatively
3-year local recurrence rate as assessed by abdominal contrast-enhanced MRI
Time Frame: 3 years postoperatively

Participants have an MRI every 3 months postoperatively

3 years postoperatively

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Circumferential resection margin negative rate
Time Frame: Immediately after the pathology results come out
Immediately after the pathology results come out
intraoperative blood loss
Time Frame: Immediately after the surgery
Immediately after the surgery
Postoperative-related complication incidence
Time Frame: From the end of surgery to 3 months postoperatively

Complications include postoperative bleeding, abdominal cavity infection, thoracic cavity infection, urinary tract infection, etc.

From the end of surgery to 3 months postoperatively
Postoperative hospital stay duration
Time Frame: From the end of surgery to discharge
From the end of surgery to discharge

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

February 8, 2026

Primary Completion (Estimated)

June 1, 2027

Study Completion (Estimated)

June 1, 2030

Study Registration Dates

First Submitted

May 8, 2026

First Submitted That Met QC Criteria

September 29, 2026

First Posted (Actual)

September 30, 2026

Study Record Updates

Last Update Posted (Actual)

September 30, 2026

Last Update Submitted That Met QC Criteria

September 29, 2026

Last Verified

May 1, 2026

More Information

Terms related to this study

Other Study ID Numbers

  • KY2025-246

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

YES

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe